Ge Healthcare Technologies Inc Stock Price, News & Analysis

GE HealthCare (GEHC) has launched Invenia ABUS Premium, an advanced 3D ultrasound system featuring AI-driven technology for breast cancer screening. The system is specifically designed for patients with dense breasts, where approximately 71% of cancers occur and traditional mammograms may miss one-third of cases.

The new system includes Verisound AI and AI Assistant, offering up to 40% faster scanning speeds and improved image quality. Key features include Scan Quality Assessment, Auto Nipple Detection, and a novel Reverse Curve transducer for enhanced patient comfort. The system's AI tools assist in detecting and characterizing breast lesions, potentially reducing unnecessary biopsies.

According to studies, 40% of women globally and 70% of Asian women have dense breast tissue, making them 4-6 times more likely to receive a breast cancer diagnosis. The system will launch in key markets throughout 2025 and has received FDA Premarket Approval.

GE HealthCare (GEHC) has announced a significant collaboration with NVIDIA at GTC 2025 to develop autonomous X-ray and ultrasound solutions. The partnership aims to address healthcare challenges including staff shortages and increasing diagnostic demands, with 4.2 billion medical imaging examinations performed annually worldwide.

The collaboration leverages NVIDIA's Isaac for Healthcare platform, built on NVIDIA's computing infrastructure for physical AI, including Omniverse for robotic simulation. GE HealthCare plans to use NVIDIA's Cosmos platform for synthetic data generation and simulation to train autonomous devices before real-world deployment.

The initiative focuses on two key areas: transforming X-ray workflows by automating repetitive tasks and developing autonomous ultrasound systems to address the 90% of sonographers reporting work-related musculoskeletal disorders. This builds on their 16-year relationship and GE HealthCare's track record of 85 FDA AI-enabled device authorizations.

GE HealthCare (GEHC) has launched the AltiX AI.i edition of Mac-Lab, CardioLab, and ComboLab, enhancing cardiac catheterization and electrophysiology procedures. This advancement comes as cardiovascular disease affects over 500 million people globally, having nearly doubled in three decades.

The new solutions offer:

• Mac-Lab: Features diastolic pressure ratio algorithm and Cath Lab Command Center access
• CardioLab: Includes Prucka 3 digital amplifier for improved signal quality and Volta Interface for AI-powered atrial fibrillation assessment
• ComboLab: Integrates EP and hemodynamic recording in a single system

AltiX AI.i is currently available for order in the United States, with global markets launch planned later this year. The company will showcase these solutions at EHRA 2025 in Vienna and HRS 2025 in San Diego.

GE HealthCare (GEHC) has unveiled its new Genesis portfolio, a cloud-based enterprise imaging software-as-a-service (SaaS) solution suite. The portfolio features four key components: edge, storage, vendor neutral archive, and data migration capabilities.

The Genesis solutions are designed to help healthcare organizations improve patient care coordination, reduce operational costs, and maintain security standards by enabling easier storage, access, and management of medical images. The platform will be deployed on Amazon Web Services (AWS), GE HealthCare's global strategic cloud provider.

This launch aligns with GE HealthCare's strategic goal to more than triple its cloud-enabled product offerings by 2028, focusing on generating recurring revenue through cloud adoption and SaaS-based models. The Genesis portfolio will be showcased at the HIMSS 2025 conference in Las Vegas.

GE HealthCare (Nasdaq: GEHC) announced a leadership transition in its China operations. Yihao Zhang, current president and CEO of China, will retire effective July 1, 2025. Will Song, a Johnson & Johnson veteran of over 20 years, will take over the position, joining on April 1, 2025.

Under Zhang's leadership since 2019, GE HealthCare achieved significant growth in China, including doubled innovation investment within five years and expanded manufacturing presence across Beijing, Wuxi, Tianjin, Shanghai, with new sites in Chengdu and Shenzhen. Zhang established a clear blueprint for regional growth through localization and innovation strategies.

Song joins from Johnson & Johnson, where he served as global senior vice president and China chairman. He holds leadership positions in various industry associations and brings extensive experience in the Chinese healthcare market. Both executives will work together to ensure a smooth transition in this strategically important region.

GE HealthCare (GEHC) has unveiled Freelium, a revolutionary sealed magnet platform for MRI systems that uses less than 1% of helium compared to conventional magnet technology. The platform builds upon GE HealthCare's lightweight intelligent magnet technology, which has achieved over 2,000 installations worldwide since 2020.

Key features of Freelium include:

• Operates without additional cooling and power requirements
• Intelligent sensor technology for remote monitoring and automated magnet protection
• Compatibility with AI-enabled solutions
• Enhanced transportability to areas with helium access

The technology aims to maintain high imaging performance while supporting sustainability goals. Through its intelligent magnet technology and Continuum upgrades, GE HealthCare has already saved approximately 3 million liters of helium.

GE HealthCare (GEHC) has begun administering the first patient doses of Flyrcado™ (flurpiridaz F 18), its newly FDA-approved PET radiotracer, at early adopter sites across the United States. This first-of-its-kind unit dose PET myocardial perfusion imaging (MPI) agent shows higher diagnostic efficacy compared to current SPECT MPI for detecting coronary artery disease (CAD).

With a significant 109-minute half-life, Flyrcado eliminates the need for onsite production and enables wider distribution. The company expects to reach nearly all existing cardiac PET centers by end of 2025, with full commercialization anticipated in Q2 2025. Houston Methodist Hospital and UW Health University Hospital are among the first adopters.

GE HealthCare has filed for CMS pass-through status to secure procedural codes and reimbursement rates, enhancing accessibility. The product enables exercise stress testing with cardiac PET imaging, offering new capabilities for CAD evaluation among the approximately 6 million annual MPI procedures in the US.

GE HealthCare (GEHC) reported strong Q4 2024 financial results with revenue growth of 2% year-over-year to $5.3 billion. The company achieved significant margin improvements, with net income margin rising to 13.5% from 7.7% and adjusted EBIT margin increasing to 18.7% from 16.1%.

For full-year 2024, GEHC posted revenue of $19.7 billion, up 1% year-over-year, with net income of $2.0 billion versus $1.6 billion in 2023. The company's performance was driven by strong demand in Advanced Visualization Solutions and Pharmaceutical Diagnostics, particularly in the U.S. market, though partially offset by softness in China.

Looking ahead to 2025, GEHC provided guidance including organic revenue growth of 2-3%, adjusted EBIT margin of 16.7-16.8%, and adjusted EPS of $4.61-$4.75. The company also announced strategic partnerships with Sutter Health and Nuffield Health, while investing $138 million in its Cork, Ireland manufacturing facility.

GE HealthCare (Nasdaq: GEHC) has announced its management team's upcoming participation at Citi's 2025 Medtech and Life Sciences Access Day. The presentation is scheduled for February 27, 2025, at 2:15 PM CT / 3:15 PM ET. Investors and interested parties can access the webcast of this event through GE HealthCare's investor relations website at investor.gehealthcare.com/news-events/events during the scheduled time.